Tracer library / [111In]DOTA-MSC3
[111In]DOTA-MSC3
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- SPECT
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- Monoclonal antibody (anti-CAIX), DOTA-conjugated
- Target / mechanism
- Carbonic anhydrase IX (CAIX), a marker of tumor hypoxia PMID 41799189
- Clinical application
- Hypoxic tumors (studied in a syngeneic mouse melanoma tumor model, B16F10-OVA) PMID 41799189
- Theranostic pair
- [225Ac]Ac-DOTA-MSC3
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | DOTA-MSC3 | 41799189 2026 Theranostics Details regarding antibody conjugation, radiolabeling and cell culture are described in the supplemental methods. |
Need this precursor?We can point you to suppliers for [111In]DOTA-MSC3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41799189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41799189: 'Monoclonal anti-CAIX antibody DOTA-MSC3 was labeled with indium-111 (111In) or actinium-225 (225Ac)'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: In-111 agent whose theranostic partner ac225-dotamsc3 carries the therapy isotope Ac-225: this is the imaging half of the pair. Linked articles: PMID 41799189. Stage set/updated at stage 39 from PMID 41799189: 'the in vivo biodistribution and dosimetry of radiolabeled DOTA-MSC3 was assessed in B16F10-OVA tumor-bearing mice'.